Use of Bode index (BI) in patients with COPD undergoing inpatient pulmonary rehabilitation (IPR) after lung resection (LR) for non small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 70s Year: 2006
Identification of occupational lung cancer (OLC) or environmental lung cancer (ELC) by lung tissue optical mineralogic analysis(LTOMA) associated to standardised questionnaire (SQ) – About sixty-five cases Source: Annual Congress 2010 - Epidemiology of lung cancer Year: 2010
Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
Induction chemotherapy (IC) followed by surgery (S) for advanced non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 463s Year: 2002
Single institution experience in advanced non-small cell lung cancer (NSCLC) patients (pts) with erlotinib (Tarceva®) within a large extended access programme* (EAP) Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006
Utility of 18 FDG-PET scan in stage 1a non small cell lung cancer (NSCLC) Source: Annual Congress 2009 - Epidemiology and management of lung cancer Year: 2009
Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Quantitative perfusion scintigraphy (QPS) or the anatomic segment method (ASM) for estimating postoperative pulmonary function (PF) in patients treated for non-small cel lung cancer (NSCLC): a retrospective comparison Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009
The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004
Prevalence of silent brain metastasis (BM) in the initial staging of non-small cell lung carcinoma (NSCLC) Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011
Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut) Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014
Late-breaking abstract: Is primary tumour standardized uptake value (SUV) an independent prognostic factor for non small cell lung cancer (NSCLC)? A meta-analysis based on individual data Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011
Biological factors predicting response to chemotherapy (CT) in advanced non small cell lung cancer (NSCLC): A feasibility study on the collection of tissue Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010
Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
Comparative analysis of lung tuberculosis (LTB) and lung cancer (LC) patients‘ smoking habits Source: Eur Respir J 2004; 24: Suppl. 48, 151s Year: 2004
Cyst-related primary lung malignancies: an important and relatively unknown imaging appearance of (early) lung cancer Source: Eur Respir Rev, 27 (150) 180079; 10.1183/16000617.0079-2018 Year: 2018
C-kit (CD 117): a new prognostic factor in small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 478s Year: 2001
Multiple primary malignancies involving lung: an analysis of 40 cases Source: Eur Respir J 2006; 28: Suppl. 50, 127s Year: 2006
Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung: LUX-Lung 8 (LL8), a phase III trial Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012